Učitavanje...
Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
ARAMIS is an international Phase III trial demonstrating the beneficial role of darolutamide, a novel anti-androgen that has been found to prolong metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. Darolutamide is a novel nonsteroidal androgen receptor antagonis...
Spremljeno u:
| Izdano u: | Asian J Androl |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wolters Kluwer - Medknow
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6958984/ https://ncbi.nlm.nih.gov/pubmed/31249268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/aja.aja_52_19 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|